Effects of dalcetrapib in patients with a recent acute coronary syndrome. - Wikidata - thesis-toulmin - TriplyDB

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

http://www.wikidata.org/entity/Q34309967

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Stabilization of high-risk plaques High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties PET Imaging of Atherosclerotic Disease: Advancing Plaque Assessment from Anatomy to Pathophysiology Hypertriglyceridemia and Cardiovascular Diseases: Revisited CETP Inhibition: Past Failures and Future Hopes Imaging Atherosclerosis.The metabolic vascular syndrome - guide to an individualized treatment Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis The role of the lymphatic system in cholesterol transport PCSK9 inhibition: the way forward in the treatment of dyslipidemia Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL Mitochondrial function and regulation of macrophage sterol metabolism and inflammatory responses Current therapies for lowering lipoprotein (a)The role of advanced lipid testing in the prediction of cardiovascular disease New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion Residual macrovascular risk in 2013: what have we learned?From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport Cardioprotective functions of HDLs Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)Niacin, an old drug with a new twist Prevention of fatal hepatic complication in schistosomiasis by inhibition of CETP Cholesterol crystals and inflammation The perils of surrogate endpoints Treatment of dyslipidemia Insights into the Tunnel Mechanism of Cholesteryl Ester Transfer Protein through All-atom Molecular Dynamics Simulations Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future New Era of Lipid-Lowering Drugs Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council Low-normal thyroid function and novel cardiometabolic biomarkers Unique features of high-density lipoproteins in the Japanese: in population and in genetic factors Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Novel methodologies for biomarker discovery in atherosclerosis

P2860

Q22241786-E716C7B2-8AAD-4123-A7E5-2258C9ACAF9F Q26738584-5998CF82-FFA0-4F2A-90C4-AE0C76C971C1 Q26746080-4E56A3DF-863C-4079-BF4B-22302E650270 Q26750603-FC12413F-202A-42DF-8E81-71CD41A9AD36 Q26750798-83B3ECAB-E0F3-4E20-BF49-BF97D57CE992 Q26750954-88009E9F-5E31-497B-87A7-C6647579A6FD Q26753158-B8B2B9DE-5B93-4DC6-B08D-868062F20EF5 Q26764836-D046C192-70E3-49AC-97D3-F2CA6AFA3291 Q26767142-D019981C-61E9-4DEF-BE05-0522CACA6E73 Q26774903-B10D813C-83A7-4CF5-B527-42561EFAD36B Q26782972-66152BD3-A19E-4017-A952-ED3266335BF2 Q26782973-B50CD318-DFCD-4178-9BBC-BEB2BD1E0C47 Q26784482-98437C86-F1EB-4592-9B7A-0EF4C64C82D6 Q26801507-3DF7981E-112F-4DB1-B44C-812BB5C70D9A Q26825337-ED14FA72-BACD-4417-9294-8EDD696F33D9 Q26830297-32B3A2CA-E51A-4D6E-8EFE-A6D90DF1E0AA Q26859507-0B00A336-AED5-4039-9536-2DA2558A462F Q26863369-1CD1FEAB-F2E8-4C0A-BAA7-4CC280CEAB03 Q26865600-E1CA5FFD-9DF3-40B8-B599-4E2E8F902055 Q26996039-55AD9974-7B38-474C-947E-56C7F17C139F Q26997647-E1C457A5-8B21-489F-A9B4-131FC4213DB6 Q27000421-0506211E-533A-472B-8F93-549CFE56B43A Q27000801-CDF0F265-EC3A-4CD6-B6C8-C273E58BE83D Q27002774-E35D15A5-327D-4EFB-BF4C-173F9CAC5B51 Q27011500-1391B4DF-CFEF-4597-BD4D-D56E35923148 Q27024737-AE397FDC-5E55-4A7F-94F6-4581F716B482 Q27025740-CE6BDE42-FBF2-4FE4-82D0-41D524D99E12 Q27026114-8FE09E32-0F40-44BE-997B-DAA040297999 Q27312096-27DC0110-03E0-4429-B5BD-375895F04363 Q27687851-34D1BA54-A409-4399-8A4D-3AAB3570EE97 Q28070061-926313A1-2209-4675-A7F1-D4528C6C32CD Q28072298-8C6C093B-EC22-4404-A7AC-A400C5DAD1CC Q28080768-AFACE36F-FEC3-4D35-8998-C56D2A2107FD Q28083058-F254B6AF-0DB7-41CE-9395-FFFAE92D8820 Q28083619-0E4156D0-CEDF-4DE8-8D2C-2D27A57D547D Q28084156-FC308793-7545-42F5-AEFF-FDA529C75E3D Q28084990-A133343B-0CF1-4616-AF63-7C81DBDB5983 Q28085611-D059AACB-1035-4AA0-916A-6E5F8CE8A9D8 Q28086787-0EC5D8DB-47B5-4F3D-841C-A147740EC991 Q28088373-4D23107D-1404-466C-BB49-A7588D3780B8

P2860

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

http://www.wikidata.org/entity/Q34309967

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@ast

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@en

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@nl

type

label

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@ast

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@en

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@nl

prefLabel

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@ast

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@en

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@nl

P1433

Q34309967-5108208C-316B-42DB-95B3-20E410033070

P1476

Q34309967-F6BC79C5-8080-46D3-8C86-EA0E9BA5593D

P2093

Q34309967-1090351B-7652-4498-B733-66843DDCCA99

Q34309967-3536145A-4890-441A-8B16-A9E205A6B767

Q34309967-42164C0C-BCF2-4E8A-B655-92D5D146A5FF

Q34309967-46CD6CFC-05F8-4778-A174-E98261FAAA92

Q34309967-68E441C7-4877-492F-900F-1839F71E5633

Q34309967-7BA1BCFD-ABAF-422D-88F3-0674C4EA9D6A

Q34309967-803A08AC-3AE9-4D22-B3B6-C4F1D108A60E

Q34309967-909AA262-3CF6-4857-9DF2-9814DAB3EF0D

Q34309967-9E7B635B-66DC-4B33-9626-DFCAA1A82606

Q34309967-A1325D89-6F75-4DCD-9D85-4AD2A9FC39B6

P304

Q34309967-32FD54A0-A219-41C0-B2D5-8D3576861C23

P31

Q34309967-606774D5-0B1D-4E4F-BEA3-CBB653FE61B4

P356

Q34309967-A118814C-1EB4-4C7B-967F-79EFDAB54683

P407

Q34309967-0AEB148F-5CBB-4457-B2EF-1DABEE0CE130

P433

Q34309967-116E6302-4163-4456-9654-40E3239BEB32

P478

Q34309967-88910376-1222-4844-B54A-CD32833293A9

P50

Q34309967-2C3C6996-B814-4F66-A5F7-A8F05D6D9E2C

P577

Q34309967-E4EF31C1-C2F4-4876-8592-D8CDA6B44CB0

P698

Q34309967-EE4866DE-EF07-4C39-9252-C2B4AAA4FEB1

P921

Q34309967-6FCB2A06-68A5-453D-AB5F-7BC07373BEDE

P356

P1433

The New England Journal of Medicine

P1476

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

@en

P2093

Anders G Olsson

http://www.w3.org/2001/XMLSchema#string

Bernard R Chaitman

http://www.w3.org/2001/XMLSchema#string

Christie M Ballantyne

http://www.w3.org/2001/XMLSchema#string

David Kallend

http://www.w3.org/2001/XMLSchema#string

Eran Leitersdorf

http://www.w3.org/2001/XMLSchema#string

Gregory G Schwartz

http://www.w3.org/2001/XMLSchema#string

Hardi Mundl

http://www.w3.org/2001/XMLSchema#string

Ingar M Holme

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Tardif

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

P304

2089-2099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1206797

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23126252

http://www.w3.org/2001/XMLSchema#string

P921